Clinical Research Organisation Contract

Clinical Research Organisation Contract

To provide services in respect of conducting a multinational Phase II study in non-cystic fibrosis BE patients.

United Kingdom-Belfast: Research services

2019/S 221-542205

Contract notice

Services

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses

Official name: Queen’s University Belfast
Postal address: University Road
Town: Belfast
NUTS code: UKN
Postal code: BT7 1NN
Country: United Kingdom
Contact person: Mrs Gillian Wasson
E-mail: g.wasson@qub.ac.uk
Telephone: +44 2890973026
I.2)Information about joint procurement

I.3)Communication

Access to the procurement documents is restricted. Further information can be obtained at: https://in-tendhost.co.uk/queensuniversitybelfast
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: https://in-tendhost.co.uk/queensuniversitybelfast
Tenders or requests to participate must be submitted to the abovementioned address

I.4)Type of the contracting authority

Body governed by public law

I.5)Main activity

Education

Section II: Object

II.1)Scope of the procurement

II.1.1)Title:

QUB/1850/19 Contract for Clinical Research Organisation

Reference number: QUB/1850/19

II.1.2)Main CPV code

73110000

II.1.3)Type of contract

Services

II.1.4)Short description:

Queen’s University Belfast seeks to appoint a Clinical Research Organisation (CRO) to provide services in respect of conducting a multinational Phase II study in non-cystic fibrosis BE patients, sponsored by Novartis, across Europe. The trial will be jointly funded by Novartis and the EU Innovative Medicines Initiative (IMI) through the iABC consortium. IMI is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients (http://www.imi.europa.eu/). Access to tender documentation is restricted to those companies who download, complete and submit a CDA to Queen’s.

II.1.5)Estimated total value

II.1.6)Information about lots

This contract is divided into lots: no
II.2)Description
II.2.1)Title:

II.2.2)Additional CPV code(s)

73110000
85121200
73111000
85145000

II.2.3)Place of performance

NUTS code: IT
NUTS code: PT
NUTS code: BE
NUTS code: FR
NUTS code: UK
NUTS code: AT
NUTS code: CH
NUTS code: DE
NUTS code: IE
NUTS code: DK
NUTS code: NL
NUTS code: ES
Main site or place of performance:

The CRO must have the capability to manage a study across multiple EU countries.

II.2.4)Description of the procurement:

Queen’s University Belfast seeks to appoint a Clinical Research Organisation (CRO) to provide services in respect of conducting a multinational Phase II study, sponsored by Novartis, across Europe.

II.2.5)Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value

II.2.7)Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24
This contract is subject to renewal: no
II.2.9)Information about the limits on the number of candidates to be invited

II.2.10)Information about variants

Variants will be accepted: yes

II.2.11)Information about options

Options: yes
Description of options:

This contract includes the option to extend by up to a further 2 years.

II.2.12)Information about electronic catalogues

II.2.13)Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:

II.2.14)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation

III.1.1)Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

III.1.2)Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3)Technical and professional ability

Selection criteria as stated in the procurement documents
III.1.5)Information about reserved contracts
III.2)Conditions related to the contract
III.2.1)Information about a particular profession

III.2.2)Contract performance conditions:

The CRO must be capable of conducting a randomised Phase II clinical study across Europe. The CRO will not be permitted to sub-contract core services under the funding guidelines and therefore must have the capacity to provide the full suite of services outlined in the specification.

III.2.3)Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1)Description

IV.1.1)Type of procedure

Competitive procedure with negotiation
IV.1.3)Information about a framework agreement or a dynamic purchasing system

IV.1.4)Information about reduction of the number of solutions or tenders during negotiation or dialogue

Recourse to staged procedure to gradually reduce the number of solutions to be discussed or tenders to be negotiated

IV.1.5)Information about negotiation

The contracting authority reserves the right to award the contract on the basis of the initial tenders without conducting negotiations
IV.1.6)Information about electronic auction

IV.1.8)Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure

IV.2.2)Time limit for receipt of tenders or requests to participate

Date: 16/12/2019
Local time: 16:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4)Languages in which tenders or requests to participate may be submitted:

English
IV.2.6)Minimum time frame during which the tenderer must maintain the tender
IV.2.7)Conditions for opening of tenders

Section VI: Complementary information

VI.1)Information about recurrence

This is a recurrent procurement: no

VI.2)Information about electronic workflows

Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used

VI.3)Additional information:

Economic operators seeking to obtain tender documentation, must first download, complete and submit a confidential disclosure agreement. Tender documents will not be issued until a completed CDA has been received.

VI.4)Procedures for review

VI.4.1)Review body

Official name: Queen’s University Belfast
Postal address: University Road
Town: Belfast
Postal code: BT7 1NN
Country: United Kingdom
Telephone: +44 2890973026Internet address: https://www.qub.ac.uk/directorates/FinanceDirectorate/Visitors/Procurement/
VI.4.2)Body responsible for mediation procedures

VI.4.3)Review procedure

Precise information on deadline(s) for review procedures:

This authority will incorporate a standstill period at the point information on the award of the contract is communicated to tenderers. That notification will provide full information on the award decision. The standstill period, which will be for a minimum of 10 calendar days, provides time for unsuccessful tenderers to challenge the award decision before the contract is entered into. The Public Contract Regulations 2015 (SI 2015/102) provide for aggrieved parties who have been harmed or are at risk of harm by a breach of the rules to take action in the High Court (England, Wales and Northern Ireland).

VI.4.4)Service from which information about the review procedure may be obtained

VI.5)Date of dispatch of this notice:

13/11/2019